Literature DB >> 17692993

A cell cycle automaton model for probing circadian patterns of anticancer drug delivery.

Atilla Altinok1, Francis Lévi, Albert Goldbeter.   

Abstract

To optimize the temporal patterning of drug delivery used in cancer chronotherapy, we resort to an automaton model describing the transitions through the successive phases of the cell cycle. The model accounts for the progressive desynchronization of cells due to the variability of the durations of the cell cycle phases, and for the entrainment of the cell cycle by the circadian clock. Focusing on the cytotoxic effect of the anticancer drug 5-fluorouracil (5-FU), which kills cells in the S phase, we compare the effect of continuous infusion of 5-FU with various circadian patterns of 5-FU administration that peak either at 4 a.m., 10 a.m., 4 p.m., or 10 p.m. The model indicates that the cytotoxic effect of 5-FU is minimum for the circadian delivery peaking at 4 a.m., and maximum for the continuous infusion or the circadian pattern peaking at 4 p.m. These results fit well with experimental observations and illustrate how the modeling approach based on the cell cycle automaton may help to predict the cytotoxic effect of anticancer drugs affecting various phases of the cell cycle.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17692993     DOI: 10.1016/j.addr.2006.09.022

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  13 in total

1.  An automaton model for the cell cycle.

Authors:  Atilla Altinok; Didier Gonze; Francis Lévi; Albert Goldbeter
Journal:  Interface Focus       Date:  2010-11-24       Impact factor: 3.906

Review 2.  Chronopharmaceutical drug delivery systems: Hurdles, hype or hope?

Authors:  Bi-Botti C Youan
Journal:  Adv Drug Deliv Rev       Date:  2010-05-12       Impact factor: 15.470

3.  Skin surface temperature rhythms as potential circadian biomarkers for personalized chronotherapeutics in cancer patients.

Authors:  Christopher G Scully; Abdoulaye Karaboué; Wei-Min Liu; Joseph Meyer; Pasquale F Innominato; Ki H Chon; Alexander M Gorbach; Francis Lévi
Journal:  Interface Focus       Date:  2011-02-06       Impact factor: 3.906

4.  Tumor growth rate determines the timing of optimal chronomodulated treatment schedules.

Authors:  Samuel Bernard; Branka Cajavec Bernard; Francis Lévi; Hanspeter Herzel
Journal:  PLoS Comput Biol       Date:  2010-03-19       Impact factor: 4.475

5.  Quantitative analysis of the effects of iododeoxyuridine and ionising radiation treatment on the cell cycle dynamics of DNA mismatch repair deficient human colorectal cancer cells.

Authors:  Evren Gurkan-Cavusoglu; Jane E Schupp; Timothy J Kinsella; Kenneth A Loparo
Journal:  IET Syst Biol       Date:  2013-08-01       Impact factor: 1.615

6.  A mathematical model for cell cycle control: graded response or quantized response.

Authors:  Guoyu Wu; Huiyu Xiu; Haiying Luo; Yu Ding; Yuchao Li
Journal:  Cell Cycle       Date:  2022-02-02       Impact factor: 5.173

Review 7.  Bridging the genotype-phenotype gap: what does it take?

Authors:  Arne B Gjuvsland; Jon Olav Vik; Daniel A Beard; Peter J Hunter; Stig W Omholt
Journal:  J Physiol       Date:  2013-02-11       Impact factor: 5.182

8.  In silico analysis of cell cycle synchronisation effects in radiotherapy of tumour spheroids.

Authors:  Harald Kempf; Haralampos Hatzikirou; Marcus Bleicher; Michael Meyer-Hermann
Journal:  PLoS Comput Biol       Date:  2013-11-14       Impact factor: 4.475

Review 9.  Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research-practice gaps, challenges, and insights.

Authors:  Ping-Pin Zheng; Jin Li; Johan M Kros
Journal:  Med Res Rev       Date:  2017-09-01       Impact factor: 12.944

10.  The Ink4a/Arf locus operates as a regulator of the circadian clock modulating RAS activity.

Authors:  Rukeia El-Athman; Nikolai N Genov; Jeannine Mazuch; Kaiyang Zhang; Yong Yu; Luise Fuhr; Mónica Abreu; Yin Li; Thomas Wallach; Achim Kramer; Clemens A Schmitt; Angela Relógio
Journal:  PLoS Biol       Date:  2017-12-07       Impact factor: 8.029

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.